MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis

Phase 4
Conditions
Hypertension
Interventions
First Posted Date
2008-04-30
Last Posted Date
2008-04-30
Lead Sponsor
University of Pavia
Target Recruit Count
75
Registration Number
NCT00669435
Locations
🇮🇹

University of Pavia, Pavia, Italy

Effects of Losartan on Insulin Resistance in Patients With Heart Failure

Phase 4
Completed
Conditions
Heart Failure
First Posted Date
2008-04-22
Last Posted Date
2008-04-22
Lead Sponsor
Tottori University Hospital
Target Recruit Count
16
Registration Number
NCT00663377

Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular

Phase 3
Conditions
Essential Hypertension
Diabetes Mellitus
Interventions
First Posted Date
2008-04-16
Last Posted Date
2008-04-16
Lead Sponsor
University of Pavia
Target Recruit Count
100
Registration Number
NCT00659451
Locations
🇮🇹

University of Pavia, Pavia, Italy

A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome

First Posted Date
2008-04-02
Last Posted Date
2010-06-09
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
44
Registration Number
NCT00651235
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension

Phase 2
Terminated
Conditions
Hypertension
Interventions
First Posted Date
2008-04-01
Last Posted Date
2009-12-01
Lead Sponsor
Pfizer
Target Recruit Count
248
Registration Number
NCT00649311
Locations
🇨🇳

Pfizer Investigational Site, Taipei, Taiwan

The Effect of Losartan on Atrial Fibrillation (AF) Burden and Pacemaker Dependence in Patients With Sick Sinus Syndrome

Not Applicable
Conditions
Atrial Fibrillation
Interventions
Drug: Placebo
First Posted Date
2008-03-31
Last Posted Date
2010-04-01
Lead Sponsor
Chung Shan Medical University
Target Recruit Count
220
Registration Number
NCT00647257
Locations
🇨🇳

Chung Shan Medical University Hospital, Taichung, Taiwan

Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency

Not Applicable
Terminated
Conditions
Renal Insufficiency, Chronic
Interventions
Drug: Benazepril+Losartan
First Posted Date
2008-03-07
Last Posted Date
2016-04-05
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
309
Registration Number
NCT00630708
Locations
🇨🇳

Renal Division, Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, China

Atacand (Candesartan) Real Life Study

Completed
Conditions
Hypertension
Interventions
First Posted Date
2008-02-21
Last Posted Date
2010-12-02
Lead Sponsor
AstraZeneca
Target Recruit Count
14000
Registration Number
NCT00620178
Locations
🇸🇪

Research Site, Uppsala, Sweden

Antihypertensive Response to Losartan and Genetic Polymorphisms

Not Applicable
Completed
Conditions
Hypertension
Interventions
First Posted Date
2008-02-18
Last Posted Date
2009-07-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
800
Registration Number
NCT00617877

Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan

Not Applicable
Completed
Conditions
Left Ventricular Hypertrophy
Renal Failure
First Posted Date
2008-01-28
Last Posted Date
2015-05-12
Lead Sponsor
Melbourne Health
Target Recruit Count
52
Registration Number
NCT00602004
Locations
🇦🇺

Royal Melbourne Hospital, Parkville, Australia

© Copyright 2025. All Rights Reserved by MedPath